LAVAL, QC, ROCKVILLE, MD
and CAMBRIDGE, United Kingdom,
Aug. 5, 2019 /CNW Telbec/
- Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCD)
(Prometic), a biopharmaceutical company focused on developing novel
therapeutics to treat unmet needs in patients with liver,
respiratory and kidney disease, today announced that members of the
management team will provide a business overview and update at the
Canaccord 39th Annual Growth Conference at 16:30 ET on
Wednesday, August 7, 2019 in
Boston, USA.
The presentation will be webcast live on the Webcasts
page of the Investors & Media section of Prometic's
website, or by following the link below in your web browser. An
archived replay of the webcast will be available on Prometic's
website for at least 7 days after the live event concludes.
http://wsw.com/webcast/canaccord35/pli/
About Prometic
Prometic (www.prometic.com) is an innovative biopharmaceutical
corporation with a broad pipeline of small molecule therapeutics
under development to treat unmet needs in patients with liver,
respiratory and kidney disease, including rare diseases. Prometic's
differentiated research involves the study of two
G-protein-coupled-receptors, GPR40 and GPR84. These drug candidates
have a dual mode-of-action as agonists ("stimulators") of GPR40 and
antagonists ("inhibitors") of GPR84. Our lead drug candidate,
PBI-4050, is expected to enter Phase 3 clinical studies for the
treatment of Alström Syndrome. A second drug candidate, PBI-4547,
is expected to enter Phase 1 clinical studies in 2019. Prometic
also has leveraged its experience in bioseparation technologies to
isolate and purify biopharmaceuticals from human plasma. The lead
plasma-derived therapeutic product is RyplazimTM
(plasminogen) which the Company expects to file a BLA with the US
FDA seeking approval to treat patients with congenital plasminogen
deficiency. The Corporation also operates a contract development
and manufacturing operation in the United
Kingdom, deriving revenue through sales of affinity
chromatography media. Prometic has active business operations in
Canada, the United States and the United Kingdom.
Forward Looking Statements
This presentation contains forward-looking statements about
Prometic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, Prometic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in the
Annual Information Form for the year ended December 31, 2018, under the heading "Risks and
Uncertainties related to Prometic's Business". As a result, we
cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by
applicable securities laws and regulations. All amounts are in
Canadian dollars unless indicated otherwise.
For more information, please visit www.prometic.com.
SOURCE ProMetic Life Sciences Inc.